The inhibitory effect of intravesical fisetin against bladder cancer by induction of p53 and down-regulation of NF-kappa B pathways in a rat bladder carcinogenesis model

Basic and Clinical Pharmacology and Toxicology

Volumn 115, Issue 4, 2014, Pages 321-329

  Li, Jing ^a   Qu, Weixing ^a   Cheng, Yongyi ^a   Sun, Yi ^a   Jiang, Yazhuo ^a   Zou, Tiejun ^a   Wang, Zhiping ^b   Xu, Yonggang ^a   Zhao, Huacai ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b LANZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FISETIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHYLNITROSOUREA; PROTEIN P53; APOPTOSIS REGULATORY PROTEIN; FLAVONOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER INHIBITION; CANCER MODEL; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; GENE EXPRESSION REGULATION; IN VIVO STUDY; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; CARCINOGENESIS; DRUG EFFECTS; DRUG SCREENING; GENETICS; INTRAVESICAL DRUG ADMINISTRATION; METABOLISM; UPREGULATION; URINARY BLADDER NEOPLASMS; WISTAR RAT;

RATTUS;

ADMINISTRATION, INTRAVESICAL; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOGENESIS; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; FLAVONOIDS; METHYLNITROSOUREA; NF-KAPPA B; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908695178     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12229     Document Type: Article

References (54)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Wirth M, Plattner VE, Gabor F. Strategies to improve drug delivery in bladder cancer therapy. Expert Opin Drug Deliv 2009;6:727-44.
3. Schenk-Braat EA, Bangma CH. Immunotherapy for superficial bladder cancer. Cancer Immunol Immunother 2005;54:414-23.
4. Griffin JG, Holzbeierlein J. Side effects of perioperative intravesical treatment and treatment strategies for these side effects. Urol Clin North Am 2013;40:197-210.
5. Fiorito C, Gontero P. [Adverse events after intravesical therapy: are we always ready to recognize and prevent them?] Urologia 2013;80(Suppl 21):27-32.
6. Bhatnagar I, Thomas NV, Kim SK. Natural flora and anticancer regime: milestones and roadmap. Anticancer Agents Med Chem 2013;13:910-22.
7. Arai Y, Watanabe S, Kimira M, Shimoi K, Mochizuki R, Kinae N. Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration. J Nutr 2000;130:2243-50.
8. Touil YS, Seguin J, Scherman D, Chabot GG. Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinomabearing mice. Cancer Chemother Pharmacol 2011;68:445-55.
9. Syed DN, Afaq F, Maddodi N, Johnson JJ, Sarfaraz S, Ahmad A et al. Inhibition of human melanoma cell growth by the dietary flavonoid fisetin is associated with disruption of Wnt/beta-catenin signaling and decreased Mitf levels. J Invest Dermatol 2011;131:1291-9.
10. Khan N, Afaq F, Khusro FH, Mustafa Adhami V, Suh Y, Mukhtar H. Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin. Int J Cancer 2012;130:1695-705.
11. Hanneken A, Lin FF, Johnson J, Maher P. Flavonoids protect human retinal pigment epithelial cells from oxidative-stressinduced death. Invest Ophthalmol Vis Sci 2006;47:3164-77.
12. Haddad AQ, Venkateswaran V, Viswanathan L, Teahan SJ, Fleshner NE, Klotz LH. Novel antiproliferative flavonoids induce cell cycle arrest in human prostate cancer cell lines. Prostate Cancer Prostatic Dis 2006;9:68-76.
13. Wu MS, Lien GS, Shen SC, Yang LY, Chen YC. HSP90 inhibitors, geldanamycin and radicicol, enhance fisetin-induced cytotoxicity via induction of apoptosis in human colonic cancer cells. Evid Based Complement Alternat Med 2013;2013:987612.
14. Ying TH, Yang SF, Tsai SJ, Hsieh SC, Huang YC, Bau DT et al. Fisetin induces apoptosis in human cervical cancer HeLa cells through ERK1/2-mediated activation of caspase-8-/caspase-3-dependent pathway. Arch Toxicol 2012;86:263-73.
15. Yang PM, Tseng HH, Peng CW, Chen WS, Chiu SJ. Dietary flavonoid fisetin targets caspase-3-deficient human breast cancer MCF-7 cells by induction of caspase-7-associated apoptosis and inhibition of autophagy. Int J Oncol 2012;40:469-78.
16. Szliszka E, Helewski KJ, Mizgala E, Krol W. The dietary flavonol fisetin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells. Int J Oncol 2011;39:771-9.
17. Murtaza I, Adhami VM, Hafeez BB, Saleem M, Mukhtar H. Fisetin, a natural flavonoid, targets chemoresistant human pancreatic cancer AsPC-1 cells through DR3-mediated inhibition of NF-kappaB. Int J Cancer 2009;125:2465-73.
18. Lim dY, Park JH. Induction of p53 contributes to apoptosis of HCT-116 human colon cancer cells induced by the dietary compound fisetin. Am J Physiol Gastrointest Liver Physiol 2009;296: G1060-8.
19. Yamaguchi H, Chen J, Bhalla K, Wang HG. Regulation of Bax activation and apoptotic response to microtubule-damaging agents by p53 transcription-dependent and -independent pathways. J Biol Chem 2004;279:39431-7.
20. Chou RH, Hsieh SC, Yu YL, Huang MH, Huang YC, Hsieh YH. Fisetin inhibits migration and invasion of human cervical cancer cells by down-regulating urokinase plasminogen activator expression through suppressing the p38 MAPK-dependent NF-kappaB signaling pathway. PLoS One 2013;8:e71983.
21. Li J, Cheng Y, Qu W, Sun Y, Wang Z, Wang H et al. Fisetin, a dietary flavonoid, induces cell cycle arrest and apoptosis through activation of p53 and inhibition of NF-kappa B pathways in bladder cancer cells. Basic Clin Pharmacol Toxicol 2011;108:84-93.
22. Arkan MC, Greten FR. IKK- and NF-kappaB-mediated functions in carcinogenesis. Curr Top Microbiol Immunol 2011;349:159-69.
23. Van Waes C. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 2007;13:1076-82.
24. Letchoumy PV, Mohan KV, Prathiba D, Hara Y, Nagini S. Comparative evaluation of antiproliferative, antiangiogenic and apoptosis inducing potential of black tea polyphenols in the hamster buccal pouch carcinogenesis model. J Carcinog 2007;6:19.
25. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol 2006;69:195-206.
26. Kunnumakkara AB, Diagaradjane P, Guha S, Deorukhkar A, Shentu S, Aggarwal BB et al. Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clin Cancer Res 2008;14:2128-36.
27. Sarkar FH, Li Y. NF-kappaB: a potential target for cancer chemoprevention and therapy. Front Biosci 2008;13:2950-9.
28. Tergaonkar V, Perkins ND. p53 and NF-kappaB crosstalk: IKKalpha tips the balance. Mol Cell 2007;26:158-9.
29. Dey A, Tergaonkar V, Lane DP. Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways. Nat Rev Drug Discovery 2008;7:1031-40.
30. Schneider G, Kramer OH. NFkappaB/p53 crosstalk-a promising new therapeutic target. Biochim Biophys Acta 2011;1815:90-103.
31. Suh Y, Afaq F, Johnson JJ, Mukhtar H. A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-kappaB-signaling pathways. Carcinogenesis 2009; 30:300-7.
32. Delto JC, Kobayashi T, Benson M, McKiernan J, Abate-Shen C. Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression. Oncotarget 2013;4:269-76.
33. Stoimenov I, Helleday T. PCNA on the crossroad of cancer. Biochem Soc Trans 2009;37:605-13.
34. Li TM, Chen GW, Su CC, Lin JG, Yeh CC, Cheng KC et al. Ellagic acid induced p53/p21 expression, G1 arrest and apoptosis in human bladder cancer T24 cells. Anticancer Res 2005;25:971-9.
35. Lee MH, Han DW, Hyon SH, Park JC. Apoptosis of human fibrosarcoma HT-1080 cells by epigallocatechin-3-O-gallate via induction of p53 and caspases as well as suppression of Bcl-2 and phosphorylated nuclear factor-kappaB. Apoptosis 2011;16:75-85.
36. Schuler M, Bossy-Wetzel E, Goldstein JC, Fitzgerald P, Green DR. p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. J Biol Chem 2000;275:7337-42.
37. Bhat TA, Nambiar D, Pal A, Agarwal R, Singh RP. Fisetin inhibits various attributes of angiogenesis in vitro and in vivo-implications for angioprevention. Carcinogenesis 2012;33:385-93.
38. Hoesel B, Schmid JA. The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer 2013;12:86.
39. Murshed F, Farhana L, Dawson MI, Fontana JA. NF-kappaB p65 recruited SHP regulates PDCD5-mediated apoptosis in cancer cells. Apoptosis 2014;19:506-17.
40. Shao H, Yang B, Hu R, Wang Y. Matrine effectively inhibits the proliferation of breast cancer cells through a mechanism related to the NF-kappaB signaling pathway. Oncol Lett 2013;6:517-20.
41. Harish Kumar G, Vidya Priyadarsini R, Vinothini G, Vidjaya Letchoumy P, Nagini S. The neem limonoids azadirachtin and nimbolide inhibit cell proliferation and induce apoptosis in an animal model of oral oncogenesis. Invest New Drugs 2010;28:392-401.
42. Jang TJ, Kang MS, Kim H, Kim DH, Lee JI, Kim JR. Increased expression of cyclin D1, cyclin E and p21(Cip1) associated with decreased expression of p27(Kip1) in chemically induced rat mammary carcinogenesis. Jpn J Cancer Res 2000;91:1222-32.
43. Shen HM, Tergaonkar V. NFkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis 2009;14:348-63.
44. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE et al. Curcumin suppresses the paclitaxelinduced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 2005;11:7490-8.
45. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 2007;109:2293-302.
46. Kundu JK, Shin YK, Kim SH, Surh YJ. Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking IkappaB kinase activity. Carcinogenesis 2006;27:1465-74.
47. Divya CS, Pillai MR. Antitumor action of curcumin in human papillomavirus associated cells involves downregulation of viral oncogenes, prevention of NFkB and AP-1 translocation, and modulation of apoptosis. Mol Carcinog 2006;45:320-32.
48. Sung B, Pandey MK, Aggarwal BB. Fisetin, an inhibitor of cyclindependent kinase 6, down-regulates nuclear factor-kappaB-regulated cell proliferation, antiapoptotic and metastatic gene products through the suppression of TAK-1 and receptor-interacting proteinregulated IkappaBalpha kinase activation. Mol Pharmacol 2007;71:1703-14.
49. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 2011;12:715-23.
50. Tergaonkar V. p53 and NFkappaB: fresh breath in the cross talk. Cell Res 2009;19:1313-5.
51. Rocha S, Perkins ND. ARF the integrator: linking NF-kappaB, p53 and checkpoint kinases. Cell Cycle 2005;4:756-9.
52. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 1998;95:8292-7.
53. Kawamoto K, Enokida H, Gotanda T, Kubo H, Nishiyama K, Kawahara M et al. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer. Biochem Biophys Res Commun 2006;339:790-6.
54. Perkins ND. NF-kappaB: tumor promoter or suppressor? Trends Cell Biol 2004;14:64-9.